Roche's BTK Inhibitor Filing Accepted for Review

Stock News09-30 16:00

Roche Holding Ltd (RHHBY.US) announced on September 30 that the U.S. FDA has accepted its New Drug Application (NDA) for the non-covalent BTK inhibitor fenebrutinib and granted it priority review for the treatment of relapsing multiple sclerosis (RMS) and primary progressive multiple sclerosis (PPMS).

According to the press release, if approved, fenebrutinib would become the first BTK inhibitor for both RMS and PPMS, as well as the first high-efficacy oral treatment option.

Fenebrutinib is an investigational non-covalent BTK inhibitor that is highly potent, highly selective, and reversible. This design allows it to act systemically and to cross the blood-brain barrier to enter the central nervous system (CNS), targeting chronic inflammation.

The acceptance of this marketing application is based on comprehensive clinical trial data for fenebrutinib, including two Phase III studies in RMS, FENhance 1 and FENhance 2, and one Phase III study in PPMS, FENtrepid. The FENhance 1 and 2 studies showed that fenebrutinib significantly reduced relapse rates, as well as active and chronic brain lesions, compared with the standard treatment teriflunomide.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1136126067?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-09-30 16:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1136126067","market":"nz","top_or_hot":-1,"title":"Roche's BTK Inhibitor Filing Accepted for Review","media":"Stock News","content":"<p>Roche Holding Ltd (RHHBY.US) announced on September 30 that the U.S. FDA has accepted its New Drug Application (NDA) for the non-covalent BTK inhibitor fenebrutinib and granted it priority review for the treatment of relapsing multiple sclerosis (RMS) and primary progressive multiple sclerosis (PPMS).<br><br>According to the press release, if approved, fenebrutinib would become the first BTK inhibitor for both RMS and PPMS, as well as the first high-efficacy oral treatment option.<br><br>Fenebrutinib is an investigational non-covalent BTK inhibitor that is highly potent, highly selective, and reversible. This design allows it to act systemically and to cross the blood-brain barrier to enter the central nervous system (CNS), targeting chronic inflammation.<br><br>The acceptance of this marketing application is based on comprehensive clinical trial data for fenebrutinib, including two Phase III studies in RMS, FENhance 1 and FENhance 2, and one Phase III study in PPMS, FENtrepid. The FENhance 1 and 2 studies showed that fenebrutinib significantly reduced relapse rates, as well as active and chronic brain lesions, compared with the standard treatment teriflunomide.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Roche's BTK Inhibitor Filing Accepted for Review</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRoche's BTK Inhibitor Filing Accepted for Review\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-09-30 16:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Roche Holding Ltd (RHHBY.US) announced on September 30 that the U.S. FDA has accepted its New Drug Application (NDA) for the non-covalent BTK inhibitor fenebrutinib and granted it priority review for the treatment of relapsing multiple sclerosis (RMS) and primary progressive multiple sclerosis (PPMS).<br><br>According to the press release, if approved, fenebrutinib would become the first BTK inhibitor for both RMS and PPMS, as well as the first high-efficacy oral treatment option.<br><br>Fenebrutinib is an investigational non-covalent BTK inhibitor that is highly potent, highly selective, and reversible. This design allows it to act systemically and to cross the blood-brain barrier to enter the central nervous system (CNS), targeting chronic inflammation.<br><br>The acceptance of this marketing application is based on comprehensive clinical trial data for fenebrutinib, including two Phase III studies in RMS, FENhance 1 and FENhance 2, and one Phase III study in PPMS, FENtrepid. The FENhance 1 and 2 studies showed that fenebrutinib significantly reduced relapse rates, as well as active and chronic brain lesions, compared with the standard treatment teriflunomide.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CANC","symbol_name":"TEMA ONCOLOGY ETF","start_time":0,"source_url":"","article_id":"1136126067","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1136126067","pubTimestamp":1790755216,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Roche Holding Ltd (RHHBY.US) announced on September 30 that the U.S. FDA has accepted its New Drug Application (NDA) for the non-covalent BTK inhibitor fenebrutinib and granted it priority review for...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"CANC":"TEMA ONCOLOGY ETF","HRTS":"Tema Heart & Health ETF","IPOS":"Renaissance International IPO ETF","RHHBY":"罗氏控股","03165":"华夏欧优股对冲","BK4007":"制药"},"translate_title":"罗氏 BTK 抑制剂申请受理审查","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"RHHBY":1,"CANC":1,"IPOS":1,"03165":1,"HRTS":1},"content_text":"Roche Holding Ltd (RHHBY.US) announced on September 30 that the U.S. FDA has accepted its New Drug Application (NDA) for the non-covalent BTK inhibitor fenebrutinib and granted it priority review for the treatment of relapsing multiple sclerosis (RMS) and primary progressive multiple sclerosis (PPMS).According to the press release, if approved, fenebrutinib would become the first BTK inhibitor for both RMS and PPMS, as well as the first high-efficacy oral treatment option.Fenebrutinib is an investigational non-covalent BTK inhibitor that is highly potent, highly selective, and reversible. This design allows it to act systemically and to cross the blood-brain barrier to enter the central nervous system (CNS), targeting chronic inflammation.The acceptance of this marketing application is based on comprehensive clinical trial data for fenebrutinib, including two Phase III studies in RMS, FENhance 1 and FENhance 2, and one Phase III study in PPMS, FENtrepid. The FENhance 1 and 2 studies showed that fenebrutinib significantly reduced relapse rates, as well as active and chronic brain lesions, compared with the standard treatment teriflunomide.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1136126067","isCrawlerRequest":true}